Bounds for the linear combinations of statistical tensors

A method of estimating the physical bounds for the linear combinations of components of statistical tensors is presented. Numerical values of the hounds for tensor combinations appearing in the additive quark model predictions for resonance production in two-body processes are calculated

Determination of statistical tensors in sequential decays

It is shown how to determine statistical tensors from the angular distributions in the decays where one of the decay products decays in turn. All tensor components may be estimated by this method, even the components of tensors $T^{L}_{M}$ with odd L (e.g. Im $\varrho _{10}$ for spin 1 particles) which cannot be measured by the usual method of moments. In addition, the decay amplitudes can be found if there are more than one coupling constants, like for spin 2 particles. Examples of decays of particles with the following spins are discussed: $1^{+} \to 0^{+} + (1^{-}\to 0 + 0)$, $2^{-} \to 0^{-} + (1^{-}\to 0 - 0)$, $\frac{3}{2}^{-} \to 0^{-} + (\frac{3}{2}^{+}\to \frac{1}{2} + 0)$, $2^{-} \to 0^{-} + (2 \to 0 + 0)$ and $1^{+} \to 0^{-} + (2^{+}\to 0 + 0)

Magnetoelastic Phase Transitions and Critical Behaviour of (Fe1−x\text{}_{1-x}Nix\text{}_{x})2\text{}_{2}P System

This report focuses on magnetoelastic properties and critical behaviour of (Fe$\text{}_{1-x}$Ni$\text{}_{x}$)$\text{}_{2}$P system. For low Ni content (x=0.01) an isolated critical point was found. Analysis of this critical behaviour in the frame of molecular field approximation was carried out. Moreover, thermal variations of the lattice parameters, as measured by X-ray diffraction techniques, were studied. The (P,T) phase diagrams obtained for several Ni contents show the evidence that the Curie temperature decreases with pressure. The Mössbauer spectra collected for x = 0.025, 0.1, 0.2, 0.25 at different temperatures are also analysed. The existence of two nonequivalent crystallographic sites occupied by iron atoms as well as local magnetic structure is discussed

Searching for atrial fibrillation: looking harder, looking longer, and in increasingly sophisticated ways. An EHRA position paper.

info:eu-repo/semantics/publishe

Natural History and Risk Stratification in Andersen-Tawil Syndrome Type 1

Background: Andersen-Tawil Syndrome type 1 (ATS1) is a rare arrhythmogenic disorder, caused by loss-of-function mutations in the KCNJ2 gene. We present here the largest cohort of patients with ATS1 with outcome data reported. Objectives: This study sought to define the risk of life-threatening arrhythmic events (LAE), identify predictors of such events, and define the efficacy of antiarrhythmic therapy in patients with ATS1. Methods: Clinical and genetic data from consecutive patients with ATS1 from 23 centers were entered in a database implemented at ICS Maugeri in Pavia, Italy, and pooled for analysis. Results: We enrolled 118 patients with ATS1 from 57 families (age 23 ± 17 years at enrollment). Over a median follow-up of 6.2 years (interquartile range: 2.7 to 16.5 years), 17 patients experienced a first LAE, with a cumulative probability of 7.9% at 5 years. An increased risk of LAE was associated with a history of syncope (hazard ratio [HR]: 4.54; p = 0.02), with the documentation of sustained ventricular tachycardia (HR 9.34; p = 0.001) and with the administration of amiodarone (HR: 268; p < 0.001). The rate of LAE without therapy (1.24 per 100 person-years [py]) was not reduced by beta-blockers alone (1.37 per 100 py; p = 1.00), or in combination with Class Ic antiarrhythmic drugs (1.46 per 100 py, p = 1.00). Conclusions: Our data demonstrate that the clinical course of patients with ATS1 is characterized by a high rate of LAE. A history of unexplained syncope or of documented sustained ventricular tachycardia is associated with a higher risk of LAE. Amiodarone is proarrhythmic and should be avoided in patients with ATS1. © 202

Metabolic syndrome is associated with similar long-term prognosis in non-obese and obese patients. An analysis of 45 615 patients from the nationwide LIPIDOGRAM 2004-2015 cohort studies

Aims We aimed to evaluate the association between metabolic syndrome (MetS) and long-term all-cause mortality. Methods The LIPIDOGRAM studies were carried out in the primary care in Poland in 2004, 2006 and 2015. MetS was diagnosed based on the National Cholesterol Education Program, Adult Treatment Panel III (NCEP/ATP III) and Joint Interim Statement (JIS) criteria. The cohort was divided into four groups: non-obese patients without MetS, obese patients without MetS, non-obese patients with MetS and obese patients with MetS. Differences in all-cause mortality was analyzed using Kaplan-Meier and Cox regression analyses. Results 45,615 participants were enrolled (mean age 56.3, standard deviation: 11.8 years; 61.7% female). MetS was diagnosed in 14,202 (31%) by NCEP/ATP III criteria, and 17,216 (37.7%) by JIS criteria. Follow-up was available for 44,620 (97.8%, median duration 15.3 years) patients. MetS was associated with increased mortality risk among the obese (hazard ratio, HR: 1.88 [95% CI, 1.79-1.99] and HR: 1.93 [95% CI 1.82-2.04], according to NCEP/ATP III and JIS criteria, respectively) and non-obese individuals (HR: 2.11 [95% CI 1.85-2.40] and 1.7 [95% CI, 1.56-1.85] according to NCEP/ATP III and JIS criteria respectively). Obese patients without MetS had a higher mortality risk than non-obese patients without MetS (HR: 1.16 [95% CI 1.10-1.23] and HR: 1.22 [95%CI 1.15-1.30], respectively in subgroups with NCEP/ATP III and JIS criteria applied). Conclusions MetS is associated with increased all-cause mortality risk in non-obese and obese patients. In patients without MetS obesity remains significantly associated with mortality. The concept of metabolically healthy obesity should be revised